stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Revenue
Teva Pharmaceutical Industries Ltd.'s revenue for fiscal 2025 was $17.3B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $17.2B. Over the past ten years it has ranged from $14.9B (fiscal 2022) to $22.4B (fiscal 2017); the current reading is higher than 64% of that period. Revenue has risen for 3 consecutive fiscal years. Teva Pharmaceutical Industries Ltd. ranks 3rd of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $17.3B | 4.32% |
| FY2024 | $16.5B | 4.40% |
| FY2023 | $15.8B | 6.17% |
| FY2022 | $14.9B | (6.00%) |
| FY2021 | $15.9B | (4.69%) |
| FY2020 | $16.7B | (1.35%) |
| FY2019 | $16.9B | (7.57%) |
| FY2018 | $18.3B | (18.38%) |
| FY2017 | $22.4B | 2.20% |
| FY2016 | $21.9B | 11.45% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $4.4B | 6.11% |
| Jun 2026 | $4.1B | 4.02% |
| Mar 2026 | $4.0B | (15.47%) |
| Dec 2025 | $4.7B | 5.16% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $30.0B |
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. | $17.2B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation compare | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TEVA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement